AngioDynamics Q3 Earnings Call Highlights

1 hour ago 1

MarketBeat

Thu, April 2, 2026 astatine 8:02 AM CDT 8 min read

AngioDynamics logo

AngioDynamics reported Q3 gross of $78.4 million, up 8.9% YoY driven by a 19% summation successful MedTech to $37.3 cardinal (now 48% of sales), and absorption raised full‑year nett income and adjusted EBITDA guidance for the 3rd consecutive quarter.
Product momentum is concentrated successful Auryon (Q3 gross $16.3M, +17.9% and the 19th consecutive double‑digit quarter); the combined mechanical thrombectomy portfolio grew ~18% with AlphaVac up 47.4% YoY and enrollment started successful the APEX‑Return pivotal trial; NanoKnife income roseate 21% alongside a caller CPT Category I codification and expanded EU indications.
Margins and cash: gross borderline fell 110 bps to 52.9% owed to tariffs and a manufacturing transition, but adjusted EBITDA improved to $1.8M and FY adjusted EBITDA guidance was raised to $10–12M; the institution had $37.8M successful cash, zero debt, and warned a $3–5M inventory physique positive $4–6M of tariff costs could marque full‑year currency travel somewhat negative.
Interested successful AngioDynamics, Inc.? Here are 5 stocks we similar better.

AngioDynamics (NASDAQ:ANGO) reported fiscal 2026 third-quarter results that absorption described arsenic “strong crossed the board,” highlighted by faster maturation successful its MedTech conception and improved adjusted EBITDA. The institution besides raised its full-year outlook for nett income and adjusted EBITDA for the 3rd consecutive quarter, citing continued execution crossed its halfway platforms.

Executive Vice President and Chief Financial Officer Steve Trowbridge said institution gross accrued 8.9% twelvemonth implicit twelvemonth to $78.4 million, with maturation successful some MedTech and Med Device. MedTech gross roseate 19% to $37.3 million, and Trowbridge noted the conception represented 48% of full gross versus 44% a twelvemonth ago, reflecting an ongoing premix shift.

→ Coursera's Options Anomaly: A Big Bet connected What's Next?

Med Device gross accrued 1.1% twelvemonth implicit year, and Trowbridge said the conception is up 3% twelvemonth to date. He characterized Med Device arsenic a accordant root of currency and profitability that supports concern successful the higher-growth MedTech platforms.

President and CEO Jim Klemmer said AngioDynamics has built its portfolio astir cardiovascular and oncology markets and pointed to 3 merchandise portfolios the institution is “really excited about.” In MedTech, Klemmer highlighted continued spot successful Auryon and what helium called an particularly beardown 4th successful mechanical thrombectomy and NanoKnife.

Auryon: Trowbridge said Auryon gross was $16.3 million, up 17.9% twelvemonth implicit year, marking the 19th consecutive 4th of double-digit growth. Klemmer said the company’s “push into the infirmary marketplace keeps paying off,” improving some maturation and economics, portion Trowbridge added the institution continues to put successful merchandise extensions specified arsenic radial entree and 1.7 mm catheters based connected doc feedback. In Q&A, absorption said maturation is being driven by some a higher infirmary premix (supporting pricing) and higher process measurement successful office-based labs, portion maintaining momentum successful some sites of care.
Mechanical thrombectomy (AlphaVac and AngioVac): Klemmer said the combined thrombectomy portfolio grew astir 18% twelvemonth implicit year, with “AlphaVac successful particular” delivering the largest sequential gross summation since launch. Trowbridge reported mechanical thrombectomy gross of $11.5 million, up 17.9%, including AlphaVac gross of $4.4 cardinal (up 47.4% twelvemonth implicit twelvemonth and much than 24% sequentially) and AngioVac gross of $7.2 cardinal (up 5%). Management attributed adoption to caller accounts, hospitals adding products done worth investigation committee (VAC) processes, and accrued utilization wrong existing accounts, supported by grooming and objective acquisition programs. Klemmer besides said the institution enrolled its archetypal patients successful the APEX-Return pivotal proceedings evaluating the AlphaReturn humor absorption strategy with AlphaVac for acute pulmonary embolism (PE), and the institution is targeting completion of the support process successful the archetypal 4th of calendar 2027.
NanoKnife: Klemmer said the 4th was beardown for some disposables and capital, and noted the CPT Category I codification became effectual January 1, with aboriginal acquisition described arsenic positive. Trowbridge said full NanoKnife gross accrued 21% to $7.6 million, with probes up 20% and superior income up 24.9%. He said probe income were chiefly driven by request successful prostate attraction and that superior placements could thrust aboriginal probe utilization arsenic adoption expands. Klemmer besides noted AngioDynamics announced expanded European indications for NanoKnife for brushed insubstantial ablation of tumors successful the liver, pancreas, kidney, and prostate, positioning NanoKnife arsenic a multi-organ level internationally.